Ovarian Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Ovarian Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Ovarian Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global ovarian cancer market. The report identifies the key trends shaping and driving the global ovarian cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ovarian cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData forecasts the global varian cancer therapeutics market to grow at 16.2% annually for the next eight years to reach $1.77 billion by 2017. It was valued at $510m in 2009. This significant growth is primarily attributed to the high prescription rates of multiple lines of chemotherapeutic drugs. In addition, the successful launch of some of the molecular targeted therapies, such as Avastin and Farletuzumab, which are currently in Phase III trials, may significantly stimulate market growth in the near future. However, the low diagnosis rate and decreasing incidence of the disease will continue to be a barrier for market growth.

Scope

The report provides information on the key drivers and challenges of the ovarian cancer market. Its scope includes:

• Annualized global ovarian cancer market revenues data from 2001 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Angiogenesis inhibitors, PAR P inhibitors, Kinase inhibitors, Antifolate, Immuno regulatory.
• Analysis of the current and future competition in the global ovarian cancer market. Key market players covered are Abbott, Pfizer, Novartis AG, Lpath Inc. and F. Hoffmann La Roche Ltd.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ovarian cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global ovarian cancer market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ovarian cancer market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global ovarian cancer market landscape? – Identify, understand and capitalize

Contents

1 TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2 OVARIAN CANCER THERAPEUTICS – INTRODUCTION

2.1 Symptoms
2.2 Diagnosis
2.3 GlobalData Pipeline Report Guidance

3 OVARIAN CANCER THERAPEUTICS – MARKET CHARACTERIZATION

3.1 Overview
3.2 Ovarian Cancer Therapeutics Market Size
3.3 Ovarian Cancer Therapeutics Market Forecast and CAGR
3.4 Drivers and Barriers for the Ovarian Cancer Therapeutics
  3.4.1 Drivers for Ovarian Cancer Therapeutics
  3.4.2 Barriers for Ovarian Cancer Therapeutics
3.5 Opportunity and Unmet Need
3.6 Key Takeaway

4 OVARIAN CANCER THERAPEUTICS – COMPETITIVE ASSESSMENT

4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in Ovarian Cancer Therapeutics
  4.3.1 Alkylating Agents (Carboplatin, Cisplatin, Melphalan and Altretamine)
  4.3.2 Anthracyclines-Doxorubicin (Doxil, Adriamycin)
  4.3.3 Taxol (paclitaxel)
  4.3.4 Gemzar (gemcitabine)
  4.3.5 Hycamtin (topotecan hydrochloride)
4.4 Key Takeaway

5 OVARIAN CANCER THERAPEUTICS – PIPELINE ASSESSMENT

5.1 Overview
5.2 Strategic Pipeline Assessment
  5.2.1 Technology Trends Analytic Framework
5.3 Ovarian Cancer Therapeutics – Promising Drugs Under Clinical Development
5.4 Molecule Profile for Promising Drugs Under Clinical Development for Ovarian Cancer
  5.4.1 Avastin (RG435, Bevacizumab)
  5.4.2 Farletuzumab (MORAb-003)
  5.4.3 Abagovomab
  5.4.4 Opaxio
  5.4.5 Telcyta
  5.4.6 Karenitecin (BNP 1350)
5.5 Ovarian Cancer Therapeutics – Clinical Pipeline by Mechanism of Action
5.6 Ovarian Cancer Therapeutics Pipeline – Pipeline by Clinical Phases of Development
  5.6.1 Ovarian Cancer Therapeutics – Regulatory and Phase III Clinical Pipeline
  5.6.2 Ovarian Cancer Therapeutics – Phase II Clinical Pipeline
  5.6.3 Ovarian Cancer Therapeutics – Phase I Clinical Pipeline
  5.6.4 Ovarian Cancer Therapeutics – Pre-clinical Pipeline
5.7 Key Takeaway

6 OVARIAN CANCER THERAPEUTICS – IMPLICATIONS FOR FUTURE MARKET COMPETITION

7 OVARIAN CANCER THERAPEUTICS – FUTURE PLAYERS IN OVARIAN CANCER THERAPEUTICS MARKET

7.1 Introduction
7.2 F. Hoffmann-La Roche Ltd/ Genentech, Inc.
  7.2.1 Overview
  7.2.2 Business Description
  7.2.3 Oncology Portfolio
7.3 BioNumerik Pharmaceuticals
  7.3.1 Overview
  7.3.2 Oncology Portfolio
7.4 Telik, Inc.
  7.4.1 Overview
  7.4.2 Business Description
  7.4.3 Oncology Products Portfolio
7.5 Morphotek, Inc. (Subsidiary of Eisai Co., Ltd.)
  7.5.1 Overview
  7.5.2 Oncology Products Portfolio
7.6 Cell Therapeutics Inc.
  7.6.1 Business Description
7.7 Menarini Group
  7.7.1 Overview
  7.7.2 Business Description
  7.7.3 Ovarian Cancer Pipeline Product Portfolio

8 OVARIAN CANCER THERAPEUTICS – APPENDIX

8.1 Market Definitions
8.2 Abbreviations
8.3 Research Methodology
  8.3.1 Coverage
  8.3.2 Secondary Research
  8.3.3 Forecasting
  8.3.4 Primary Research
  8.3.5 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Sources

LIST OF TABLES

Table 1: Ovarian Cancer, Classification and Treatment Protocol Stages
Table 2:Ovarian Cancer Therapeutics, Global , Revenue ($m), 2001-2009
Table 3: Ovarian Cancer Therapeutics, Global, Forecast ($m), 2009-2017
Table 4: Ovarian Cancer Therapeutics , Gemzar – Adverse Reactions
Table 5: Ovarian Cancer Therapeutics , Hycamtin – Adverse Reactions
Table 6: Major Marketed Product Comparison in Ovarian Cancer Therapeutics Market, 2010
Table 7: Ovarian Cancer Therapeutics – Promising Drugs Under Clinical Development, 2010
Table 8: Ovarian Cancer Therapeutics – Regulatory and Phase III Clinical Pipeline, 2010
Table 9: Ovarian Cancer Therapeutics – Phase II Clinical Pipeline, 2010
Table 10: Ovarian Cancer Therapeutics – Phase I Clinical Pipeline, 2010
Table 11: Ovarian Cancer Therapeutics – Pre-clinical and Discovery Pipeline, 2010
Table 12: F. Hoffmann-La Roche Ltd/Genentech, Inc. – Oncology Pipeline Products, 2010
Table 13: F. Hoffmann-La Roche Ltd/Genentech, Inc. – Ovarian Cancer Pipeline Products, 2010
Table 14: BioNumerik Pharmaceuticals, Inc. – Oncology Pipeline Products, 2010
Table 15: BioNumerik Pharmaceuticals, Inc. – Ovarian Cancer Pipeline Products, 2010
Table 16: Telik, Inc. – Oncology Pipeline Products, 2010
Table 17: Telik, Inc. – Ovarian Cancer Pipeline Products, 2010
Table 18: Morphotek/Eisai – Oncology Pipeline Products, 2010
Table 19: Morphotek/Eisai – Ovarian Cancer Pipeline Products, 2010
Table 20: Cell Therapeutics, Inc. – Oncology Pipeline Products, 2010
Table 21: Cell Therapeutics, Inc. – Oncology Pipeline Products, 2010
Table 22: Menarini Group – Ovarian Cancer Pipeline Products, 2010

LIST OF FIGURES

Figure 1: Ovarian Cancer Therapeutics , Global, Revenue ($m), 2001-2009
Figure 2: Ovarian Cancer Therapeutics, Global, Forecast ($m), 2009-2017
Figure 3: Opportunity and Unmet Need in the Ovarian Cancer Therapeutics , 2010
Figure 4: Strategic Competitor Assessment of the Major Marketed Products in Ovarian Cancer, 2010
Figure 5: Technology Trends Analytic Framework of the Ovarian Cancer Therapeutics Pipeline, 2010
Figure 6: Technology Trends Analytic Framework of the Ovarian Cancer Therapeutics Pipeline – Description, 2010
Figure 7: Ovarian Cancer Therapeutics – Clinical Pipeline by Mechanism of Action, 2010
Figure 8: Ovarian Cancer Therapeutics Pipeline by Phase of Clinical Development, 2010
Figure 9: Implications for Future Market Competition in the Ovarian Cancer, 2010
Figure 10: Ovarian Cancer Therapeutics – Clinical Pipeline by Company, 2010
Figure 11: GlobalData Market Forecasting Model

COMPANIES MENTIONED

F. Hoffmann-La Roche Ltd/ Genentech, Inc.
BioNumerik Pharmaceuticals
Telik, Inc.
Morphotek, Inc. (Subsidiary of Eisai Co., Ltd.)
Cell Therapeutics Inc.
Menarini Group Skip to top